Treatment of Schamberg's disease with pentoxifylline - therapeutic trial

ABSTRACT

Thirty patients with Schamberg's disease were started on pentoxifylline [400 mg three times daily] for a period of 9 weeks. Improvement was assessed at 3 weekly intervals by two observers independently and graded as mild [<25%], moderate [25-50%] and marked [>50%]. Marked improvement was observed in 15/30 [50%] patients. We conclude that pentoxifylline should be considered as first line therapy in all patients with Schamberg's disease